Adverum Biotechnologies, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ADVM Nasdaq 2830 adverum.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adverum Biotechnologies, Inc.

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 5th, 2025 2:01 pm
Adverum Biotechnologies: Q1 Earnings Snapshot - May 14th, 2025 2:33 pm
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights - May 14th, 2025 2:05 pm
3 Penny Stocks Under $300M Market Cap To Consider - May 6th, 2025 6:05 am
Adverum Biotechnologies: Q4 Earnings Snapshot - Apr 15th, 2025 5:47 am
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones - Apr 15th, 2025 5:40 am
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 4th, 2025 2:05 pm
Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference - Mar 31st, 2025 2:01 pm
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD - Mar 3rd, 2025 2:01 pm
Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference - Feb 25th, 2025 5:00 am
3 US Penny Stocks With Market Caps Below $400M - Feb 18th, 2025 10:11 am
Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Feb 5th, 2025 2:05 pm
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Nov 20th, 2024 2:05 pm
Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell - Nov 18th, 2024 6:16 am
Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements - Nov 18th, 2024 5:00 am
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements - Nov 15th, 2024 2:05 pm
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates - Nov 4th, 2024 4:00 pm
Adverum Biotechnologies: Q3 Earnings Snapshot - Nov 4th, 2024 3:06 pm
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones - Nov 4th, 2024 2:39 pm
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program - Oct 16th, 2024 6:00 am